SYBX - Synlogic Profit before interest, taxes and amortization
Synlogic, Inc. (SYBX) develops synthetic biologics for metabolic correction in US laboratories. The base EBITDA reflects pre-tax cash flow dynamics, where the 0.00 indicator determines the metric's value. Revenue prospects relied on the commercialization of modified probiotics, but the ecosystem has now been completely destroyed, and asset liquidation has led to the final closure of the business.
Summary analytical data breakdowns for Synlogic (SYBX)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization data:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
SYBX - Company Net Income|Future Profit Synlogic, Inc.|SYBX - Price to Earnings Ratio|Market Cap to Projected Earnings Synlogic Inc.|SYBX - Price/Earnings to Growth Multiple|Company Value to EBITDA Synlogic|SYBX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Synlogic|SYBX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months synlogictx.com|SYBX - Earnings per share growth in current year|Expected net earnings per share growth next year Synlogic, Inc.
Analysis of all company metrics:Synlogic, Inc. (SYBX)
Investors must monitor the actual liquidity of Synlogic, Inc. (SYBX), as laboratory equipment supply chain disruptions can instantaneously drain operating cash flow. Analyzing aggregate EBITDA allows for the identification of hidden cash shortages prior to the publication of reports, separating actual cash inflows from accounting profits and warning of business leverage risks.
Who Synlogic, Inc. competes with
ASND - Operating profit before deduction of amortization|Madrigal Pharmaceuticals - Operating profit EBITDA|Profit before interest, taxes and amortization corcept.com|RYTM (Rhythm Pharmaceuticals, Inc.) - Operating profit before deduction of amortization|AKRO: Company profit before taxes, interest and amortization|MTSR (Metsera Corp) - Operating profit EBITDA|Operating profit EBITDA MoonLake Corp|Operating profit EBITDA CRNX|Profit before payment of interest, taxes and amortization NAMS (newamsterdampharma.com)|Profit before payment of interest, taxes and amortization Soleno Therapeutics, Inc. SLNO|Amicus Therapeutics Inc (FOLD) - Profit before interest, taxes and amortization|ETNB - Profit before payment of interest, taxes and amortization|AGIO: Profit before payment of interest, taxes and amortization|GPCR: Operating profit EBITDA|MDXG - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Rezolute|Lexicon Pharmaceuticals Inc (LXRX) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization MBX Bio (MBX)|Operating profit before deduction of amortization Altimmune Pharma ALT|Profit before payment of interest, taxes and amortization Aardvark Therapeutics Inc AARD|Operating income before deduction of amortization sagimet.com (SGMT)|BIOA: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Biomea Fusion Inc|quincetx.com (QNCX) - Profit before payment of interest, taxes and amortization|Operating profit before amortization GUTS|Profit before payment of interest, taxes and amortization vTv Therapeutics, Inc.|Profit before payment of interest, taxes and amortization ATPC|Profit before payment of interest, taxes and amortization Pluri Inc. (PLUR)|LPCN - Profit before interest, taxes and amortization|Operating profit EBITDA MTNB (Matinas BioPharma Holdings)|Operating profit before depreciation charges sprucebiosciences.com|Galecto, Inc. - Operating profit EBITDA|Operating income before deduction of amortization carmellrx.com CTCX|LUMO: Operating profit EBITDA|Operating profit before deduction of amortization Organovo Holdings|Operating profit before deduction of amortization RDUS
